Ideaya Biosciences vs Rhythm Pharmaceuticals
Ideaya Biosciences is the larger business, with $219m of revenue in fiscal 2025 against $190m for Rhythm Pharmaceuticals (1.2 times as much). Ideaya Biosciences grew faster (3024.4% against 45.8%). Ideaya Biosciences kept more of each dollar of sales as profit: a net margin of -52.0% against -103.6%. Ideaya Biosciences carries less debt relative to equity (0.0% against 77.8%).
| Latest fiscal year | Ideaya BiosciencesIDYA, 2025 | Rhythm PharmaceuticalsRYTM, 2025 |
|---|---|---|
| Revenue | $219m | $190m |
| Revenue growth | 3024.4% | 45.8% |
| Net income | −$114m | −$197m |
| Operating margin | -72.8% | -101.2% |
| Net margin | -52.0% | -103.6% |
| Return on equity | -10.9% | — |
| Free cash flow | −$73.5m | −$117m |
| Cash | $113m | $54.3m |
| Total debt | $0 | $108m |
| Debt to equity | 0.0% | 77.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 145 | 414 |
| Market value | $3.05bn | $6.43bn |
| Price vs our value range | — | — |
| Moat score | — | 25 (Weak) |
| Insider trades, 12 months | 1 buys, 3 sales | 0 buys, 50 sales |